NRx Pharmaceuticals, Inc. (NRXP) Tops Q3 EPS by 4c

NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) reported Q3 EPS of ($0.07), $0.04 better than the analyst estimate of ($0.11). Revenue for the quarter came in at $0 versus the consensus estimate of $0 .

For earnings history and earnings-related data on NRx Pharmaceuticals, Inc. (NRXP) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Cerebras Q1 EPS miss sends shares down 9% after-hours
• FedEx (FDX) Tops Q4 EPS by 39c, Beats on Revenue; Offers FY27 EPS Guidance